Study S002745

HOMA-PULSE: Assessment of Glucose Metabolism and Insulin Resistance as a Predictor of Pulsed Field Ablation Success in Atrial Fibrillation

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07551947
Acronym: HOMA-PULSE
Study type: OBSERVATIONAL
Status: ENROLLING_BY_INVITATION
Enrollment: 120
Start: 2026-04-01
Primary completion: 2028-12
Lead sponsor: Nemocnice AGEL Trinec-Podlesi a.s.
Conditions: Atrial Fibrillation; Insulin Resistance; Catheter Ablation; Artificial Intelligence
Results posted: FALSE
Individual participant data sharing: UNDECIDED
Secondary identifiers: OTHER:EK KLH_EK_01_HOMA PULSE; OTHER_GRANT:INT2025003

Registered primary outcomes

Rate of Reablation at 4-5 Months [4 to 5 months after primary PFA ablation]
Prevalence of Insulin Resistance in Non-Diabetic AF Patients Undergoing PFA [Baseline (day of ablation)]
Association Between HOMA-IR and Reablation Risk [Baseline HOMA-IR measurement to reablation decision at 4-5 months post-ablation]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.